Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis

Wei Zhang, Shichun Lun, Shu Huan Wang, Xing Wu Jiang, Fan Yang, Jie Tang, Abigail L. Manson, Ashlee M. Earl, Hendra Gunosewoyo, William Ramses Bishai, Li Fang Yu

Research output: Contribution to journalArticle

Abstract

Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.

Original languageEnglish (US)
Pages (from-to)791-803
Number of pages13
JournalJournal of Medicinal Chemistry
Volume61
Issue number3
DOIs
StatePublished - Feb 8 2018

Fingerprint

Mycolic Acids
Antitubercular Agents
Polyketide Synthases
Mycobacterium tuberculosis
Benzofurans
High-Throughput Nucleotide Sequencing
Drug Discovery
Cyclization
Structure-Activity Relationship
Biological Products
Serum
Biological Availability
Single Nucleotide Polymorphism
X-Rays
Genome
Phenotype
Genes
coumestan
benzofuran

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. / Zhang, Wei; Lun, Shichun; Wang, Shu Huan; Jiang, Xing Wu; Yang, Fan; Tang, Jie; Manson, Abigail L.; Earl, Ashlee M.; Gunosewoyo, Hendra; Bishai, William Ramses; Yu, Li Fang.

In: Journal of Medicinal Chemistry, Vol. 61, No. 3, 08.02.2018, p. 791-803.

Research output: Contribution to journalArticle

Zhang, Wei ; Lun, Shichun ; Wang, Shu Huan ; Jiang, Xing Wu ; Yang, Fan ; Tang, Jie ; Manson, Abigail L. ; Earl, Ashlee M. ; Gunosewoyo, Hendra ; Bishai, William Ramses ; Yu, Li Fang. / Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. In: Journal of Medicinal Chemistry. 2018 ; Vol. 61, No. 3. pp. 791-803.
@article{e670c821545b4d44b2719fbc9f8ee8bb,
title = "Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis",
abstract = "Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.",
author = "Wei Zhang and Shichun Lun and Wang, {Shu Huan} and Jiang, {Xing Wu} and Fan Yang and Jie Tang and Manson, {Abigail L.} and Earl, {Ashlee M.} and Hendra Gunosewoyo and Bishai, {William Ramses} and Yu, {Li Fang}",
year = "2018",
month = "2",
day = "8",
doi = "10.1021/acs.jmedchem.7b01319",
language = "English (US)",
volume = "61",
pages = "791--803",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis

AU - Zhang, Wei

AU - Lun, Shichun

AU - Wang, Shu Huan

AU - Jiang, Xing Wu

AU - Yang, Fan

AU - Tang, Jie

AU - Manson, Abigail L.

AU - Earl, Ashlee M.

AU - Gunosewoyo, Hendra

AU - Bishai, William Ramses

AU - Yu, Li Fang

PY - 2018/2/8

Y1 - 2018/2/8

N2 - Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.

AB - Inhibition of the mycolic acid pathway has proven a viable strategy in antitubercular drug discovery. The AccA3/AccD4/FadD32/Pks13 complex of Mycobacterium tuberculosis constitutes an essential biosynthetic mechanism for mycolic acids. Small molecules targeting the thioesterase domain of Pks13 have been reported, including a benzofuran-based compound whose X-ray cocrystal structure has been very recently solved. Its initial inactivity in a serum inhibition titration (SIT) assay led us to further probe other structurally related benzofurans with the aim to improve their potency and bioavailability. Herein, we report our preliminary structure-activity relationship studies around this scaffold, highlighting a natural product-inspired cyclization strategy to form coumestans that are shown to be active in SIT. Whole genome deep sequencing of the coumestan-resistant mutants confirmed a single nucleotide polymorphism in the pks13 gene responsible for the resistance phenotype, demonstrating the druggability of this target for the development of new antitubercular agents.

UR - http://www.scopus.com/inward/record.url?scp=85041891996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041891996&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01319

DO - 10.1021/acs.jmedchem.7b01319

M3 - Article

C2 - 29328655

AN - SCOPUS:85041891996

VL - 61

SP - 791

EP - 803

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 3

ER -